Publications

Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, Taioli E, Fryzek J. 2022. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS One 17(8):e0271339; doi: 10.1371/journal.pone.0271339. PMID: 36040901.

Pouillot R, Farakos SS, Spungen J, Schaefer HR, Flannery BM, Van Doren JM. 2022. Cadmium physiologically based pharmacokinetic (PBPK) models for forward and reverse dosimetry: Review, evaluation, and adaptation to the U.S. population. Toxicol Lett 367(Aug):67-75; doi: 10.1016/j.toxlet.2022.07.812. PMID: 35901988. Corrigendum: Toxicol Lett 2023 377(March):14-15; doi: 10.1016/j.toxlet.2023.01.011.

Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. Mortality associated with respiratory syncytial virus, bronchiolitis, and influenza among infants in the United States: A birth cohort study from 1998 to 2018. J Infect Dis 226(Suppl 2):S246–S254; doi: 10.1093/infdis/jiac127. PMID: 35968877.

Bylsma LC, Suh M, Movva N, Fryzek JP, Nelson CB. 2022. Mortality among United States infants and children under 5 years of age with respiratory syncytial virus and bronchiolitis: A systematic literature review. J Infect Dis 226(Suppl 2):S267–S281; doi: 10.1093/infdis/jiac226. PMID: 35968871.

Movva N, Suh M, Bylsma LC, Fryzek JP, Nelson CB. 2022. Systematic literature review of respiratory syncytial virus laboratory testing practices and incidence in United States infants and children <5 years of age. J Infect Dis 226(Suppl 2):S213–S224; doi: 10.1093/infdis/jiac203. PMID: 35968874.

Suh M, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. A systematic literature review of the burden of respiratory syncytial virus disease and health care utilization among United States infants younger than 1 year. J Infect Dis 226(Suppl 2):S195–S212; doi: 10.1093/infdis/jiac201. PMID: 35968876.

Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus burden and healthcare utilization in United States infants, <1 year of age: Study of nationally representative databases, 2011–2019. J Infect Dis 226(Suppl 2):S184–S194; doi: 10.1093/infdis/jiac155. PMID: 35968879.

Movva N, Suh M, Reichert H, Hitze B, Sendak MP, Wolf Z, et al. 2022. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: A retrospective cohort study of a health system. J Infect Dis 226(Suppl 2):S175–S183; doi: 10.1093/infdis/jiac220. PMID: 35968868.

Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus (RSV) is the leading cause of United States infant hospitalizations 2009–2019: A study of the National (Nationwide) Inpatient Sample. J Infect Dis 226(Suppl 2):S154–S163; doi: 10.1093/infdis/jiac120. PMID: 35968878.

Wheeler MW, Cortiñas Abrahantes J, Aerts M, Gift JS, Allen Davis J. 2022. Continuous model averaging for benchmark dose analysis: Averaging over distributional forms. Environmetrics 33(5):e2728; doi: 10.1002/env.2728. PMID: 36589902.

Haber LT, Pecquet AM, Vincent MJ, White LM. 2022. The long goodbye: Finally moving on from the relative potency approach to a mixtures approach for polycyclic aromatic hydrocarbons (PAHs). Int J Env Res Pub Health 19(15):9490; doi: 10.3390/ijerph19159490. PMID: 35954852.

House JS, Grimm FA, Klaren WD, Dalzell A, Kuchi S, Zhang S, Lenz K, Boogaard PJ, Ketelsegers HB, Gant TW, Wright FA, Rusyn I. 2022. Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays. ALTEX 39(3):388-404; doi: 10.14573/altex.2107051. PMID: 35288757.

Rankin DA, Haddadin Z, Lipworth L, Stahl AL, Fryzek J, Suh M, et al. 2022. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee. Therapeut Adv Infect Dis 9(July 18):20499361221112171; doi: 10.1177/20499361221112171. PMID: 35875809.

Ponder J, Rajagopal R, Singal M, Baker N, Patlewicz G, Roggen E, Cochrane S, Sullivan K. 2022. “In Litero” screening. Retrospective evaluation of clinical evidence to establish a reference list of human chemical respiratory sensitizers. Front Toxicol 4(Jul 15):916370; doi: 10.3389/ftox.2022.916370. PMID: 35910543.

Karmaus A, Mansouri K, To K, Blake B, Fitzpatrick J, Strickland J, Patlewicz G, Allen D, et al. 2022. Evaluation of variability across rat acute oral systemic toxicity studies. Toxicol Sci 188(1):34-47; doi: 10.1093/toxsci/kfac042. PMID: 35426934.

Tsvetkov L, Pittsenbarger J, Atsriku C, Devine P, Dingley K, et al. 2022. Inhibition of CDC7 with Sgr-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents. Blood 140 (Sup 1):5961–5962; doi: 10.1182/blood-2022-167239.

Roell K, Koval LE, Boyles R, Patlewicz G, Ring C, Rider CV, Ward-Caviness C, Reif D, et al. 2022. Development of the intelligence and machine learning toolkit (TAME) for introductory data science, chemical-biological analyses, predictive modelling, and database mining for environmental health research. Front Toxicol 4(Jun 22):893924; doi: 10.3389/ftox.2022.893924. PMID: 35812168.

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9. PMID: 34331235.

Alexander AW, Jensen IJ, Hathaway J, Srivastava K, Cyr PL, Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197. PMID: 35343812.

Price C. 2022. Syntheses synthesized: A look back at Grant and Booth’s review typology. Evid-based Libr Info Prac 17(2):132–138; doi: 10.18438/eblip30093.